MedTrace Logo

Efficacy of a Gamified Augmented Reality Exposure-based Application in Subjects With Fear of Spiders

NCT04162509 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-12-20

No results posted yet for this study

Summary

Investigation of the efficacy of a gamified augmented reality exposure app in individual with fear of spiders.

Conditions

  • Fear of Spiders

Interventions

OTHER

AR app

Participants will be exposed to nine different AR spider scenarios with a pre-defined length of 2 minutes for each level. Each level starts with a surface scan of the environment and the placement of the AR spider model(s) by tapping on the display. Through small text pop-ups the user is instructed to perform different tasks (e.g. looking at the spider model, approaching it, holding the hand under the model). They proceed to further levels according to a predefined exposure scheme based on SUDS for fear (scale 0=no fear to 10=maximum fear) and disgust (scale 0=no disgust to 10=maximum disgust) and the assurance of the task completed (yes/no). Users will repeat each level until their SUDS are 4 or below and have completed the task. Each exposure session is limited to approx. 30 minutes (controlled by the participants) irrespective of achieved level.

Sponsors & Collaborators

  • Swiss National Science Foundation

    collaborator OTHER

  • Prof. Dominique de Quervain, MD

    lead OTHER

Principal Investigators

  • Dominique de Quervain, Prof. · University of Basel

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-07
Primary Completion
2019-12-04
Completion
2019-12-04

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04162509 on ClinicalTrials.gov